Paul Choi
Stock Analyst at Goldman Sachs
(4.35)
# 1,240
Out of 4,457 analysts
374
Total ratings
54.5%
Success rate
9.2%
Average return
Main Sectors:
Stocks Rated by Paul Choi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EWTX Edgewise Therapeutics | Rated: Hold | $20 → $32 | $40.92 | -21.80% | 3 | Jun 17, 2026 | |
| VERA Vera Therapeutics | Maintained: Buy | $95 → $90 | $43.15 | +108.57% | 4 | Jun 5, 2026 | |
| URGN UroGen Pharma | Maintained: Hold | $16 → $18 | $36.07 | -50.10% | 23 | May 18, 2026 | |
| RGNX REGENXBIO | Maintained: Hold | $12 → $10 | $11.83 | -15.47% | 11 | May 14, 2026 | |
| CRVS Corvus Pharmaceuticals | Maintained: Buy | $40 | $14.48 | +176.24% | 3 | May 14, 2026 | |
| ARVN Arvinas | Maintained: Sell | $6 | $8.29 | -27.62% | 8 | May 12, 2026 | |
| BBIO BridgeBio Pharma | Maintained: Buy | $112 → $116 | $72.01 | +61.09% | 35 | May 8, 2026 | |
| LNTH Lantheus Holdings | Maintained: Hold | $77 → $94 | $109.58 | -14.22% | 5 | May 7, 2026 | |
| EXEL Exelixis | Maintained: Buy | $50 | $54.28 | -7.89% | 8 | May 6, 2026 | |
| VIR Vir Biotechnology | Maintained: Buy | $21 | $10.38 | +102.31% | 25 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $95 → $101 | $87.26 | +15.75% | 10 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $10.87 | - | 18 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $255 | $263.70 | -3.30% | 25 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $75 | $60.13 | +24.73% | 12 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $3 | $3.15 | -4.76% | 13 | Mar 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | $12 | $15.92 | -24.62% | 27 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $8 → $0.5 | $0.164 | +204.88% | 9 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | $50 → $55 | $81.57 | -32.57% | 25 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $32 → $55 | $62.41 | -11.87% | 18 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $4.09 | n/a | 1 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $7.31 | n/a | 25 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.29 | n/a | 5 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $19 | $10.71 | n/a | 19 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $57.67 | n/a | 1 | Jun 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $133.32 | $17.01 | n/a | 1 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $19 | $4.86 | n/a | 5 | Jun 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $25 → $3.5 | $8.56 | n/a | 4 | Apr 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $8 → $7 | $8.19 | n/a | 8 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $12 → $9 | $13.20 | n/a | 5 | Sep 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 → $17 | $95.68 | n/a | 3 | Mar 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $50 | $7.24 | n/a | 1 | Nov 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | n/a | $150,000.00 | n/a | 2 | Aug 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $135 | $170.00 | n/a | 4 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | $18 → $20 | $65.39 | n/a | 5 | Mar 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $135 → $165 | $114.66 | n/a | 2 | Nov 1, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $90 | $1,229.93 | n/a | 1 | Apr 7, 2017 |
Edgewise Therapeutics
Jun 17, 2026
Rated: Hold
Price Target: $20 → $32
Current: $40.92
Upside: -21.80%
Vera Therapeutics
Jun 5, 2026
Maintained: Buy
Price Target: $95 → $90
Current: $43.15
Upside: +108.57%
UroGen Pharma
May 18, 2026
Maintained: Hold
Price Target: $16 → $18
Current: $36.07
Upside: -50.10%
REGENXBIO
May 14, 2026
Maintained: Hold
Price Target: $12 → $10
Current: $11.83
Upside: -15.47%
Corvus Pharmaceuticals
May 14, 2026
Maintained: Buy
Price Target: $40
Current: $14.48
Upside: +176.24%
Arvinas
May 12, 2026
Maintained: Sell
Price Target: $6
Current: $8.29
Upside: -27.62%
BridgeBio Pharma
May 8, 2026
Maintained: Buy
Price Target: $112 → $116
Current: $72.01
Upside: +61.09%
Lantheus Holdings
May 7, 2026
Maintained: Hold
Price Target: $77 → $94
Current: $109.58
Upside: -14.22%
Exelixis
May 6, 2026
Maintained: Buy
Price Target: $50
Current: $54.28
Upside: -7.89%
Vir Biotechnology
May 6, 2026
Maintained: Buy
Price Target: $21
Current: $10.38
Upside: +102.31%
May 5, 2026
Reiterated: Buy
Price Target: $95 → $101
Current: $87.26
Upside: +15.75%
Apr 30, 2026
Maintained: Hold
Price Target: n/a
Current: $10.87
Upside: -
Apr 8, 2026
Maintained: Buy
Price Target: $255
Current: $263.70
Upside: -3.30%
Mar 10, 2026
Maintained: Buy
Price Target: $75
Current: $60.13
Upside: +24.73%
Mar 3, 2026
Maintained: Hold
Price Target: $3
Current: $3.15
Upside: -4.76%
Feb 25, 2026
Maintained: Sell
Price Target: $12
Current: $15.92
Upside: -24.62%
Feb 24, 2026
Downgraded: Hold
Price Target: $8 → $0.5
Current: $0.164
Upside: +204.88%
Dec 3, 2025
Maintained: Sell
Price Target: $50 → $55
Current: $81.57
Upside: -32.57%
Oct 29, 2025
Maintained: Buy
Price Target: $32 → $55
Current: $62.41
Upside: -11.87%
Feb 11, 2025
Downgraded: Hold
Price Target: n/a
Current: $4.09
Upside: n/a
Dec 19, 2024
Rated: Hold
Price Target: n/a
Current: $7.31
Upside: n/a
Dec 19, 2024
Rated: Hold
Price Target: n/a
Current: $1.29
Upside: n/a
Jul 31, 2024
Maintained: Hold
Price Target: $19
Current: $10.71
Upside: n/a
Jun 4, 2024
Maintained: Buy
Price Target: n/a
Current: $57.67
Upside: n/a
Nov 10, 2023
Maintained: Hold
Price Target: $133.32
Current: $17.01
Upside: n/a
Jun 28, 2023
Maintained: Buy
Price Target: $19
Current: $4.86
Upside: n/a
Apr 3, 2022
Downgraded: Hold
Price Target: $25 → $3.5
Current: $8.56
Upside: n/a
Nov 5, 2021
Maintained: Hold
Price Target: $8 → $7
Current: $8.19
Upside: n/a
Sep 22, 2021
Downgraded: Hold
Price Target: $12 → $9
Current: $13.20
Upside: n/a
Mar 4, 2021
Maintained: Buy
Price Target: $15 → $17
Current: $95.68
Upside: n/a
Nov 9, 2020
Initiated Coverage: Buy
Price Target: $50
Current: $7.24
Upside: n/a
Aug 24, 2020
Maintained: Sell
Price Target: n/a
Current: $150,000.00
Upside: n/a
Jun 29, 2020
Downgraded: Hold
Price Target: $135
Current: $170.00
Upside: n/a
Mar 30, 2020
Upgraded: Hold
Price Target: $18 → $20
Current: $65.39
Upside: n/a
Nov 1, 2017
Maintained: Buy
Price Target: $135 → $165
Current: $114.66
Upside: n/a
Apr 7, 2017
Reiterated: Buy
Price Target: $90
Current: $1,229.93
Upside: n/a